Advances in Fecal Tests for Colorectal Cancer Screening
Open Access
- 29 January 2016
- journal article
- research article
- Published by Springer Nature in Current Treatment Options in Gastroenterology
- Vol. 14 (1) , 152-162
Abstract
Opinion statement Colorectal cancer (CRC) forms an important public health problem, especially in developed countries. CRC screening tests can be used to identify asymptomatic individuals with CRC precursors and (early) cancer. Removal of these lesions reduces CRC incidence and prevents CRC-related mortality. There are a range of screening tests available, each with advantages and disadvantages. Stool screening tests can broadly be divided into fecal occult blood tests (FOBTs) and molecular biomarker test, such as DNA/RNA marker tests, protein markers, and fecal microbiome marker tests. Guaiac fecal occult blood tests (gFOBT) have been demonstrated in large randomized screening trials to reduce CRC mortality. Fecal immunochemical tests (FIT) have superior adherence, usability, and accuracy as compared to gFOBT. Advantage of the use of quantitative FITs in CRC screening programs is the cut-off level that can be adjusted. Molecular biomarker DNA tests have shown to detect significantly more cancers than FIT. By combining biomarker DNA tests with FIT, sensitivity for advanced adenomas can be increased significantly. However, it has lower specificity thus demands more colonoscopy resources, is more cumbersome, and costly. The adherence has not been assessed in population screening trials. For these reasons, FIT is therefore at present regarded as the preferred method of non-invasive CRC screening. This chapter will review the current status of fecal test-based CRC screening.Keywords
This publication has 58 references indexed in Scilit:
- Colonoscopic Polypectomy and Long-Term Prevention of Colorectal-Cancer DeathsNew England Journal of Medicine, 2012
- Sensitivity of immunochemical faecal occult blood testing for detecting left- vs right-sided colorectal neoplasiaBritish Journal of Cancer, 2011
- Comparison of Guaiac-Based and Quantitative Immunochemical Fecal Occult Blood Testing in a Population at Average Risk Undergoing Colorectal Cancer ScreeningAmerican Journal of Gastroenterology, 2010
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008International Journal of Cancer, 2010
- Effect of Rising Chemotherapy Costs on the Cost Savings of Colorectal Cancer ScreeningJNCI: Journal of the National Cancer Institute, 2009
- Screening for colorectal cancer: random comparison of guaiac and immunochemical faecal occult blood testing at different cut-off levelsBritish Journal of Cancer, 2009
- Survival benefit in a randomized clinical trial of faecal occult blood screening for colorectal cancerBritish Journal of Surgery, 2008
- Screening and Surveillance for the Early Detection of Colorectal Cancer and Adenomatous Polyps, 2008: A Joint Guideline From the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of RadiologyGastroenterology, 2008
- Randomised study of screening for colorectal cancer with faecal-occult-blood testThe Lancet, 1996
- Randomised controlled trial of faecal-occult-blood screening for colorectal cancerThe Lancet, 1996